[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

Press release: Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials

Commentaries: Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results – TIME AND Novavax Says Vaccine Is 96% Effective At Preventing Original Covid-19 Virus – Forbes

Commentary on Twitter

https://twitter.com/m_scribe/status/1370126020121083913